Press release
Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Target FGFR2, IDH1/2, and Beyond | DelveInsight
Intrahepatic Cholangiocarcinoma Pipeline Insight
DelveInsight's "Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a detailed analysis of the therapeutic development landscape for iCCA, a rare but highly lethal form of bile duct cancer with limited curative options. The majority of patients are diagnosed at an advanced stage, and median survival remains poor, underscoring the need for targeted and immune-based innovations.
Several promising therapies are in late-stage clinical trials, including futibatinib (TAS-120), a next-generation irreversible FGFR inhibitor, and ivosidenib for IDH1-mutant iCCA. Immunotherapies such as durvalumab, nivolumab, and anti-PD-1/CTLA-4 combinations are also being explored, either alone or in synergy with chemotherapy. Novel multi-kinase inhibitors, antibody-drug conjugates, and tumor microenvironment modulators are expanding the treatment armamentarium.
The FDA continues to grant orphan drug designations and breakthrough therapy status to accelerate development in this underserved space. Biomarker testing and molecular profiling are increasingly being integrated into standard diagnostic algorithms, enhancing trial enrollment and personalization of therapy.
As 2025 approaches, the iCCA pipeline is shifting from empirical treatment to targeted, biology-driven approaches-empowered by molecular diagnostics, real-world evidence, and strong academic-industry collaboration. With multiple registrational trials underway, the landscape is poised for significant progress in improving survival and quality of life for patients with this challenging disease.
Interested in learning more about the current treatment landscape and the key drivers shaping the Intrahepatic Cholangiocarcinoma pipeline? Click here [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Key Takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report
- DelveInsight's Intrahepatic cholangiocarcinoma pipeline analysis depicts a strong space with 18+ active players working to develop 20+ pipeline drugs for Intrahepatic cholangiocarcinoma treatment.
- The leading Intrahepatic cholangiocarcinoma companies include Zymeworks, Basilea Pharmaceuticals, Medivir AB, Amgen, Kinnate Biopharma, Tyra Biosciences, Trisalus Life Sciences, and others are evaluating their lead assets to improve the Intrahepatic cholangiocarcinoma treatment landscape.
- Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.
- In April 2025, researchers published results linking molecular resistance mechanisms in FGFR2-altered iCCA to futibatinib treatment, showing genomic correlates and evolving resistance pathways identified through ctDNA profiling and tissue biopsies; the analysis aims to guide future sequencing of FGFR inhibitors.
- In May 2024, the FDA announced the final withdrawal of its accelerated approval for infigratinib (Truseltiq) in FGFR2-positive cholangiocarcinoma. The withdrawal was requested by the sponsor due to challenges in conducting the required confirmatory trial for clinical benefit
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic cholangiocarcinoma (ICC) is a rare and aggressive form of liver cancer that originates in the bile ducts within the liver. It often presents at an advanced stage due to its subtle symptoms, making early diagnosis challenging. ICC is characterized by rapid tumor growth and poor prognosis, with limited treatment options available. Current therapies include surgical resection for eligible patients, chemotherapy, targeted therapies, and emerging immunotherapies aimed at improving outcomes. Research is ongoing to better understand the molecular mechanisms driving ICC to develop more effective treatments.
Find out more about Intrahepatic cholangiocarcinoma medication at https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Intrahepatic Cholangiocarcinoma Treatment Analysis: Drug Profile
Zanidatamab: Zymeworks
Zanidatamab is an investigational bispecific antibody developed using Zymeworks' proprietary Azymetric platform, designed to simultaneously bind two distinct HER2 epitopes through biparatopic binding. This unique approach enables multiple mechanisms of action, including dual HER2 signaling blockade, HER2 protein removal from the cell surface, and immune-mediated cytotoxicity, resulting in promising antitumor effects. Zanidatamab is currently in Phase III clinical trials as a targeted therapy for patients with HER2-expressing solid tumors, including intrahepatic cholangiocarcinoma.
HMPL-453: Hutchmed
HMPL-453 is a novel, highly selective small molecule inhibitor targeting FGFR 1, 2, and 3. Preclinical studies have shown that HMPL-453 offers superior potency and kinase selectivity compared to other FGFR inhibitors, along with a favorable safety profile. It is currently being evaluated in Phase II clinical trials for the treatment of intrahepatic cholangiocarcinoma.
Learn more about the novel and emerging intrahepatic cholangiocarcinoma pipeline therapies [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].
Intrahepatic Cholangiocarcinoma Therapeutics Assessment
By Product Type
- Mono
- Combination
- Mono/Combination.
By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
By Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
By Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Scope of the Intrahepatic Cholangiocarcinoma Pipeline Report
- Coverage: Global
- Key Intrahepatic Cholangiocarcinoma Companies: Zymeworks, Basilea Pharmaceuticals, Medivir AB, Amgen, Kinnate Biopharma, Tyra Biosciences, Trisalus Life Sciences, and others.
- Key Intrahepatic Cholangiocarcinoma Pipeline Therapies: Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.
Explore detailed insights on drugs used in the treatment of intrahepatic cholangiocarcinoma here [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].
Table of Contents
1. Introduction
2. Executive Summary
3. Intrahepatic Cholangiocarcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
6. Intrahepatic Cholangiocarcinoma Pipeline: Late-Stage Products (Phase III)
7. Intrahepatic Cholangiocarcinoma Pipeline: Mid-Stage Products (Phase II)
8. Intrahepatic Cholangiocarcinoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intrahepatic-cholangiocarcinoma-pipeline-insight-2025-20-emerging-therapies-target-fgfr2-idh12-and-beyond-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Target FGFR2, IDH1/2, and Beyond | DelveInsight here
News-ID: 4128509 • Views: …
More Releases from ABNewswire
West Chester Showroom Reports Increased Interest in Sectional Couches and Afford …
Furniture & Cabinet Outlet serves West Chester's growing community with wholesale-priced home furnishings, offering extensive showroom selections and below-retail pricing for residents of the Tri-State area.
West Chester Township, OH - As housing markets shift and homeowners seek affordable ways to refresh their living spaces, Furniture & Cabinet Outlet continues to serve the Tri-State area with wholesale-priced home furnishings. The Service Center Drive showroom has become a destination for residents searching…
Beauty Shots NOVA Redefines Non-Surgical Body Contouring in Northern Virginia
Founder Natascha Harris pioneers ultrasound-guided aesthetic treatments for safer, natural-looking results.
Image: https://www.abnewswire.com/upload/2025/10/c5a5f59da37c1aa322df6881e23a4d74.jpg
Vienna, VA - In an era where safety and results are equally vital in aesthetics, Beauty Shots NOVA, led by founder and aesthetic specialist Natascha Harris, is setting a new standard in non-surgical beauty care. Located at 8607 Westwood Center Dr, Suite 100 in Vienna, Virginia, the premier medspa is revolutionizing body contouring and cosmetic enhancement through ultrasound-guided procedures…
Abby Yoga Studio Expands with Private Yoga Therapy Sessions
Certified Yoga Therapy instructor offers tailored Iyengar-based practices for health needs.
Image: https://www.abnewswire.com/upload/2025/10/f6b927744919d106273aa8b6f23c144c.jpg
Abbotsford, BC - Abby Yoga Studio has introduced private yoga therapy sessions, focusing on personalized assessments and adapted practices for individuals or small groups. Applying Iyengar yoga therapy principles, these one-on-one or limited-group classes address physical and emotional challenges, integrating mind-body healing to restore natural function.
Led by Eileen Millar, a Level Three certified Iyengar teacher and C-IAYT yoga therapist,…
Zil Money Launches ZilRemit as Dedicated International Payment Platform
New Standalone Platform Offers Seamless, Low-Cost Global Payments for Businesses and Personal Use, with Easy App Access and Faster Transaction Processing.
Image: https://www.abnewswire.com/upload/2025/10/491fa4dc34bd8bd434ab18aeac2e7e4f.jpg
TYLER, TX, USA - Oct 09, 2025 - Zil Money, a leading B2B payment platform, today announced the launch of ZilRemit, a dedicated platform for its international payment services. The new platform provides a focused identity for the company's high-speed, low-cost global payment solution, enabling businesses and individuals to…
More Releases for Intrahepatic
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Growth, Trends, Cons …
Introduction
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of rare, inherited liver disorders characterized by defective bile secretion, leading to chronic cholestasis, liver damage, and progressive liver failure. PFIC typically manifests in infancy or early childhood and, without intervention, often requires liver transplantation at a young age.
For decades, treatment options were limited to symptomatic relief and surgical interventions. However, with the approval of bile acid transporter inhibitors, alongside the emergence…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
Intrahepatic Cholangiocarcinoma Market Generated Opportunities, Future Scope 202 …
The intrahepatic cholangiocarcinoma market is estimated to be valued at USD 1.10 billion in 2025 and is expected to reach USD 1.90 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
According to the latest research from CoherentMI, the Intrahepatic Cholangiocarcinoma Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Progressive Familial Intrahepatic Cholestasis Pipeline: Promising Therapies Shap …
The treatment landscape for Progressive Familial Intrahepatic Cholestasis (PFIC), a rare and progressive liver disorder, is evolving rapidly, driven by innovative therapies from leading pharmaceutical and biotech companies. Key players such as Mirum Pharmaceuticals and Vivet Therapeutics are advancing therapeutic options focused on addressing the root causes of cholestasis, including bile acid regulation and hepatic transport. These emerging treatments aim to improve liver function, reduce pruritus, and delay the progression…
Transjugular Intrahepatic Portosystemic Shunt (TIPS) Boston Scientific Corporati …
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding and refractory ascites. It involves creating a shunt between the portal and hepatic veins, bypassing the liver to reduce portal pressure. TIPS is performed under fluoroscopic guidance by interventional radiologists. It effectively alleviates symptoms and reduces the risk of complications associated with portal hypertension. TIPS is typically reserved for…
Intrahepatic Cholangiocarcinoma Pipeline Insight and Clinical Trial Phases Repor …
DelveInsight's, "Intrahepatic Cholangiocarcinoma Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the Intrahepatic Cholangiocarcinoma pipeline drug profiles, including Intrahepatic Cholangiocarcinoma clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Intrahepatic…
